Non-Hodgkin Lymphoma News

• Screen All New Cancer Patients for Hepatitis? With no identifiable risk factors in most cases, universal screening before cancer therapy may prevent life-threatening complications.
  Medscape Medical News, January 2019
• NCCN Guidelines Downloaded 10 Million Times in 2018 The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology were downloaded 10 million times in 2018, which is a 26% increase from the previous year.
  Medscape Medical News, January 2019
• Early-Onset Sjögren's Linked to More Severe Disease Early-onset Sjogren's syndrome may be linked to more severe disease that worsens over time and has specific symptoms at presentation, a study found.
  Medscape Medical News, December 2018
• Histological Subtype Best Outcome Predictor in Orbital Lymphoma How well orbital lymphoma (OL) patients do depends mainly on which of four subtypes they have, a new case series suggests.
  Reuters Health Information, December 2018
• Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.
  Reuters Health Information, December 2018
• ASH 2018'Marginal Benefit' With Rivaroxaban in Cancer Patients The oral drug rivaroxaban was used for prophylaxis against primary venous thromboembolism in ambulatory cancer patients treated in the outpatient setting.
  Medscape Medical News, December 2018
• ASH 2018Four Cycles of CHOP Instead of Six for Favorable DLBCL Patients with favorable-prognosis DLBCL receiving four cycles of R-CHOP followed by two additional cycles of rituximab had outcomes similar to those in patients receiving six cycles.
  Medscape Medical News, December 2018
• ASH 2018CAR T Cells: 'Validation That They Keep Living and Keep Working' New longer-term data on CAR T cells from pivotal clinical trials show durable responses, with some patients remaining in remission for years after one infusion.
  Medscape Medical News, December 2018
• Polymorphisms Tied to Bexarotene Side Effects in Cutaneous Lymphoma Screening for APOA5 and APOC3 polymorphisms in patients with cutaneous T-cell lymphoma might help identify those less likely to experience hypertriglyceridemia associated with bexarotene treatment, according to Spanish researchers.
  Reuters Health Information, November 2018
• Groundskeeper in Bayer U.S. Weed-Killer Case Accepts Reduced Award The school groundskeeper who won a jury trial against Bayer AG's Monsanto unit over allegations that the company's glyphosate-containing weed-killers caused his cancer, accepted a court-mandated reduced punitive damages award on Wednesday.
  Reuters Health Information, November 2018
• Macrophage Checkpoint Blockade: New Immunotherapy Strategy A new immunotherapy strategy targets the macrophage and innate immunity. The remarkable response seen in non-Hodgkin's lymphoma paves the way for this approach in other malignancies.
  Medscape Medical News, October 2018
• U.S. Judge Affirms Monsanto Weed-Killer Verdict, Slashes Damages A U.S. judge on Monday affirmed a verdict against Bayer AG unit Monsanto that found its glyphosate-based weed-killers responsible for a man's terminal cancer, sending the German company's shares down 8 percent.
  Reuters Health Information, October 2018
• Eating More Organic Food Tied to Lower Cancer Risk A huge observational study from France surveyed adults online about food consumption and then followed them for a mean of 5 years.
  Medscape Medical News, October 2018
• ESMO 2018Gender Differences in Chemo Side Effects Although outcomes and rates overall toxicity of esophagogastric cancer chemotherapy are similar for men and women, rates of nausea, diarrhea, and hair loss are higher in women, warn UK scientists.
  Medscape Medical News, October 2018
• No Chemo; Rituximab Alone for Indolent Lymphoma? New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.
  Medscape Medical News, October 2018
• 'Unexpected': Age 35 Key to Ovarian Function After Chemo for HL Age impacts recovery of ovarian function after chemotherapy for Hodgkin's lymphoma, even when regimens considered less toxic are used.
  Medscape Medical News, October 2018
• Rare Manufacturing Glitch Raises Concern Over CAR-T Therapies: Study A single leukemia cell inadvertently got mixed in with a batch of a patient's immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported on Monday.
  Reuters Health Information, October 2018
• Risk of Second Primary Cancer on the Rise in People With HIV
  Reuters Health Information, September 2018
• Europe OKs Brigatinib for ALK+NSCLC, Other Products A positive opinion was granted for brigatinib, as well as mogamulizumab, a generic version of paclitaxel, and three new biosimilar pegfilgrastim products.
  Medscape Medical News, September 2018
• 'Watchful Waiting' for Early Follicular Lymphoma Questioned Regarding the management of early follicular lymphoma, an editorial examines the available options and asks why watchful waiting should be an option when it is not curative.
  Medscape Medical News, September 2018